Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Added to Dual or Triple Treatment in Patients with Type 2 Diabetes Mellitus

被引：0
作者：
Yesol Hong
Yoomin Jeon
Yoona Choi
Tae Kyu Chung
Howard Lee
机构：
[1] Seoul National University,Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology
[2] Seoul National University,Department of Applied Bioengineering, Graduate School of Convergence Science and Technology
[3] Seoul National University College of Medicine and Hospital,Department of Clinical Pharmacology and Therapeutics
[4] Center for Convergence Approaches in Drug Development,undefined
来源：
Diabetes Therapy | 2024年 / 15卷
关键词：
Diabetes mellitus, type 2; Blood glucose; Observational study; Sodium-glucose transporter 2 inhibitors; Hypoglycemic agents;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：487 / 496
页数：9
相关论文
共 96 条
  • [1] Cosentino F(2021)9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes–2022 Diabetes Care 45 S125-S143
  • [2] Grant PJ(2019)2019 Clinical practice guidelines for type 2 diabetes mellitus in Korea Diabetes Metab J 43 398-406
  • [3] Aboyans V(2020)2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD Eur Heart J 41 255-323
  • [4] Vivian EM(2014)Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents Drugs Context 3 1543-1556
  • [5] Van Baar MJB(2018)SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management Diabetes Care 41 783-794
  • [6] van Ruiten CC(2016)Efficacy diabetes mellitus: systematic review and network meta-analysis Diabetes Obes Metab 18 323-334
  • [7] Muskiet MHA(2021)Comprehensive analysis of adverse events associated with SGLT2is: a meta-analysis involving nine large randomized trials Front Endocrinol (Lausanne) 12 2295-2306
  • [8] van Bloemendaal L(2018)Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (canagliflozin cardiovascular assessment study) Circulation 137 347-357
  • [9] Jzerman RGI(2019)Canagliflozin and renal outcomes in type 2 diabetes and nephropathy N Engl J Med 380 644-657
  • [10] van Raalte DH(2019)Dapagliflozin and cardiovascular outcomes in type 2 diabetes N Engl J Med 380 387-393
12345678910